Characterization by flow cytometry of fluorescent, selective agonist

probes of the A3 adenosine receptor by Eszter, Kozma et al.
Characterization by Flow Cytometry of Fluorescent, Selective
Agonist Probes of the A3 Adenosine Receptor
Eszter Kozmaa, Elizabeth T. Gizewskib, Dilip K. Tosha, Lucia Squarcialupia, John A.
Auchampachb, and Kenneth A. Jacobsona,*
aMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of
Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
20892-0810.
bDepartment of Pharmacology and Toxicology and the Cardiovascular Center, Medical College of
Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226.
Abstract
Various fluorescent nucleoside agonists of the A3 adenosine receptor (AR) were compared as high
affinity probes using radioligands and flow cytometry (FCM). They contained a fluorophore
linked through the C2 or N6 position and rigid A3AR-enhancing (N)-methanocarba modification.
A hydrophobic C2-(1-pyrenyl) derivative MRS5704 bound nonselectively. C2-Tethered cyanine5-
dye labeled MRS5218 bound selectively to hA3AR expressed in whole CHO cells and
membranes. By FCM, binding was A3AR-mediated (blocked by A3AR antagonist, at least half
through internalization), with t1/2 for association 38 min in mA3AR-HEK293 cells; 26.4 min in
sucrose-treated hA3AR-CHO cells (Kd 31 nM). Membrane binding indicated moderate mA3AR
affinity, but not selectivity. Specific accumulation of fluorescence (50 nM MRS5218) occurred in
cells expressing mA3AR, but not other mouse ARs. Evidence was provided suggesting that
MRS5218 detects endogenous expression of the A3AR in the human promyelocytic leukemic
HL-60 cell line. Therefore, MRS5218 promises to be a useful tool for characterizing the A3AR.
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1. Introduction
The A3 adenosine receptor (AR) belongs to the Group A (rhodopsin-like) of G protein-
coupled receptors (GPCRs). The human (h) A3AR is widespread throughout the body but
generally at low levels, with expression noted in the lung, liver, brain, heart and eyes [1].
Based on in vitro and in vivo experiments, the A3AR represents a promising new target in
drug discovery with cerebro- and cardioprotective, anti-cancer, anti-inflammatory and anti-
asthmatic effects [2–7]. The A3AR is upregulated in diseased tissue, such as tumors and
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inflamed arthritic joints [1,2]. Several A3AR agonists are in advanced clinical trials for
hepatocellular carcinoma, psoriasis and other conditions.
Activation of the hA3AR results in inhibition of adenylyl cyclase via Gi protein with a
subsequent decrease in the level of 3′,5′-cyclic adenosine monophosphate (cAMP).
Subsequent to agonist binding, the hA3AR can be phosphorylated by GPCR kinases (GRKs)
followed by the binding of β-arrestins, which cause desensitization of the hA3AR and have
their own signaling pathways. Receptor desensitization is associated with receptor
internalization by clustering in clathrin-coated pits within minutes [8].
Agonist-induced regulation of the hA3AR has been studied by means of
immunoprecipitation assays [9], adenylyl cyclase assays [10] and immunogold electron
microscopy [11], or with radiolabeled ligands [12]. It has been reported that agonist-bound
hA3ARs exist within highly ordered membrane domains [13], which has increased the need
to study receptor-ligand interactions via potent and selective labeled ligands of the hA3AR.
Radioligands used for receptor characterization suffer from various disadvantages: limited
range of visualization techniques and the cost and health risk associated with their usage and
disposal. Thus, fluorescent receptor ligands of high affinity are of interest as novel tools for
characterization of the A3AR.
Fluorescent ligands for different AR subtypes have been used to study sub-cellular receptor
localization [14], to quantify ligand-receptor interactions at the level of single cells [15] and
as probes in receptor binding assays [16] in low or high throughput screening mode [17].
The use of fluorescent conjugates in ligand binding assays enables the real-time
visualization and quantitation of the receptor and ligand-receptor interactions. Many of the
fluorescent ligands used for binding assays or quantification of ARs are antagonists [16–18],
which are suitable for labeling GPCRs on intact cells because they are not internalized, but
agonists are useful for studying internalization. Therefore, our objective was the
characterization of novel potent and selective fluorescent A3AR agonists to enable
fluorescent binding experiments on intact cells and to allow the quantification of receptor
internalization using flow cytometry (FCM) and fluorescence microscopy.
In this study, we compare the binding properties, potency and selectivity of eight fluorescent
derivatives of adenine nucleosides (Figure 1), including five previously reported nucleosides
(1 – 5) and three derivatives (6 – 8) prepared for this study. All contained a fluorophore
linked through either the C2 or N6 position of the adenine ring. Furthermore, the rigid (N)-
methanocarba ([3.1.0-bicyclohexane]) ring modification that enhances A3AR selectivity is
present in all of the derivatives [19,20].
2. Materials and methods
2.1. Reagents
Isomeric pyrene derivatives 2 (MRS5704) and 3 [21], C2-tethered Alexa Fluor 488
derivatives 1 (MRS5218) and 4 [19,22] and squaraine-rotaxane derivative 5 (structure of the
fluorophore is undisclosed) [19] were prepared as described previously. IR dye 700 DX
derivative 6 (C2-tethered) was prepared by amide formation, and Alexa Fluor 488
derivatives 7 and 8, both of which are N6-tethered, were synthesized by the general methods
of click coupling of azido (fluorophore) and terminal alkyne (pharmacophore) components
used to prepare a series of 1,2,3-triazole derivatives as A3AR agonists [20]. The Cy5 N-
hydroxysuccinimide ester (variation containing an N-ethyl group) for preparation of 1 was
purchased from GE Healthcare Life Sciences (Piscataway, NJ) or from Selleckchem.com
(Houston, TX). The probes were purified using HPLC as described [20] to demonstrate
>95% purity. Characterization by NMR using a 400MHz Advance™ III HD-NanoBay
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(Bruker BioSpin Corp., Billerica, MA, USA) and by high resolution mass spectrometry
(proteomics optimized Micromass Q-TOF-2 (Waters, Milford, MA) using external
calibration with polyalanine) confirmed the assigned structure.
The fluorescent probes were stored as solids at −80 °C and diluted with DMSO as
concentrated stock solutions before the experiments. DMEM and F12 were purchased from
Mediatech, Inc. (Herndon, VA), and hygromycin B and fetal bovine serum (FBS) were from
Cellgro (Manassas, VA). Costar 6- 12- and 96-well plates, Penicillin-Streptomycin-
Glutamine (PSG), G418, sucrose, Cl-IB-MECA and NECA were purchased from Sigma (St.
Louis, MO). CGS21680, CPA, IB-MECA, MRS1220 and XAC were from Tocris R&D
Systems, Inc. (Minneapolis, MN). Quantum Cy5 MESF beads for quantification of
fluorescence intensity [31] were purchased from Bangs Laboratories, Inc. (Fishers, IN).
[3H]R-N6-Phenylisopropyladenosine ([3H]R-PIA, 63 Ci/mmol), [125I]N6-(4-amino-3-
iodobenzyl)adenosine-5′-N-methyluronamide ([125I]I-AB-MECA, 2200 Ci/mmol), and [3H]
(2-[p-(2-carboxyethyl)phenyl-ethylamino]-5′-N-ethylcarboxamido-adenosine)
([3H]CGS21680, 40.5 Ci/mmol) were purchased from PerkinElmer Life and Analytical
Science (Boston, MA).
2.2. Absorbance and fluorescence measurements
The absorbance and the fluorescence spectra of 10 µM MRS5704 in DMSO, methanol, PBS
or in Tris buffer and 2 µM MRS5218 in methanol was measured in a cuvette, using the
corresponding solvent as reference. The effects of the addition of 50 µg/well cell membrane
were measured in 96-well black plates using Tris buffer as a reference. The membranes were
incubated at 22 °C with 70 nM, 200 nM or 1 µM MRS5704 and the fluorescence was
measured after 5 min and 60 min. The final volume was 200 µl in each well. All spectra
were measured with a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale,
CA).
2.3. Cell cultures and ligand treatment
Chinese hamster ovary (CHO) cells stably expressing the human (h) A3AR were grown in
DMEM/F12 (1:1) medium with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin/
streptomycin in the presence of 500 µg/ml hygromycin B. Human embryonic kidney cells
(HEK293) stably expressing mouse (m) ARs were grown in DMEM medium with 10%
FBS, 2 mM L-glutamine, 50 U/ml penicillin/streptomycin, and 0.6 mg/ml G418. Cells used
for FCM analysis were grown in 6-, 12- or 24-well plates (approximately 4 × 105, 2 × 105 or
1 × 105 cells/well, respectively) and incubated at 37 °C for 24 h in the presence of 5% CO2.
When the confluency reached 80% (approximately 106, 5 × 105 or 2.5 × 105 cells/well),
medium was replaced with fresh medium in the presence or absence of 0.4 M sucrose, and
MRS5218 was added in the presence or absence of a competitive agonist or antagonist.
When the cells were incubated with sucrose-containing medium, there was a 15 min
preincubation period before ligand was added. Cells were then incubated for up to 2 h at 4 or
37 °C. To study receptor internalization, after washing, cells were washed with 1 ml of ice-
cold acid stripping buffer (DMEM with 0.2% BSA - bovine serum albumin - adjusted to pH
3.5 with HCl) three times for 5 min on shaking platform at 4 °C to remove surface bound
ligand, and washed three times with ice-cold PBS for 5 min on shaking platform [23].
Competitive binding assays were performed as follows: CHO cells expressing the hA3AR
were grown in 96-well plates. When the cells reached the 70% confluency, medium was
changed to 0.2 ml fresh medium containing 0.4 M sucrose and cells were preincubated for
15 min. 30 nM MRS5218 was added along with increasing concentrations of the tested
known AR igands. Cells were incubated for 1 h at 37 °C, then washed three times with 0.2
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ml PBS. 0.2 ml 0.2 % EDTA was added to each well, incubated for 15 min at 37 °C and
homogenized on shaker for 15 min at 24 °C at 700rpm.
HL-60 cells were obtained from the American Type Culture Collection (Manassas, VA) and
grown in RPMI 1640 medium with 2 mM L-glutamine, 20% FBS, and antibiotics.
2.4. Radioligand binding assays (hARs)
Competition radioligand binding assays were conducted with cell membranes prepared from
transfected CHO cells expressing hARs. For preparing cell membranes, after harvest and
homogenization, the cells were centrifuged at 1000 × g for 5 min at 4 °C, and the pellet was
resuspended in 50 mM Tris buffer (Tris–HCl buffer, pH 7.5, containing 10 mM MgCl2).
The suspension was homogenized with an electric homogenizer for 10 s and recentrifuged at
25,000 × g for 30 min at 4 °C. The resultant membrane pellets were resuspended in buffer in
the presence of 3 units/ml adenosine deaminase and incubated at 37 °C in a water bath for 1
h, and the suspension was stored at −80 °C until the binding experiments. The protein
concentration was measured using the Bradford assay [24].
Into each tube in the binding assay was added 50 µl of increasing concentrations of the test
ligand in Tris−HCl buffer (50 mM, pH 7.5) containing 10 mM MgCl2, 50 µl of the
appropriate agonist radioligand, and finally 100 µl of membrane suspension. The agonist
radioligands [3H]R-PIA (final concentration of 3.5 nM), [3H]CGS21680 (10 nM) and
[125I]I-AB-MECA (0.34 nM) were used in assays with the hA1AR (22 μg protein/tube), the
hA2AAR (20 µg/tube), and the hA3AR (21 µg/tube), respectively. Nonspecific binding was
determined using a final concentration of 10 µM adenosine-5′-N-ethylcarboxamide (NECA)
diluted with the buffer. The mixtures were incubated at 25 °C for 60 min in a shaking water
bath. Binding reactions were terminated by filtration through Brandel GF/B filters under
reduced pressure using an M-24 cell harvester (Brandel, Gaithersburg, MD). Filters were
washed three times with 3 ml of 50 mM ice-cold Tris−HCl buffer (pH 7.5). Filters for A1
and A2AAR binding were placed in scintillation vials containing 5 ml of Hydrofluor
scintillation buffer and counted using a Tri-Carb 2810TR Liquid Scintillation Analyzer
(PerkinElmer, Waltham, MA). Filters for A3AR binding were counted using a Packard
Cobra II γ-counter.
2.5. Radioligand binding assays (mARs)
Similar competition binding assays were conducted with HEK293 cell membranes
expressing mARs using [125I]I-AB-MECA to label A1 or A3ARs and [3H]CGS21680 to
label A2AARs [25]. Nonspecific binding was determined in the presence of 100 µM NECA.
2.6. Fluorescent microscopy experiments
CHO cells stably expressing the hA3AR were grown on sterile coverslips in 6-well plates,
and experiments were performed when the cells reached 70% confluency after refreshing the
medium. The cells were incubated with 70 nM MRS5218 for different time intervals ranging
from 5 min to 2 h at 37 °C in an atmosphere containing 5% CO2. At the end of each time
interval, the medium was removed, and cells were washed three times with ice-cold PBS
(Crystalgen, Commack, NY). The coverslips containing the cells were placed on sterile
slides, and the cells were observed under a Zeiss AxioCam MRm fluorescence microscope
(Carl Zeiss, Inc., Thornwood, NY).
2.7. FCM calibration
To quantify the number of receptor-bound ligands, we used quantitative fluorescence
calibration [31]. To convert measured fluorescence intensity (MFI) values into molecules of
equivalent soluble fluorochrome (MESF) values, we used Quantum Cy5 MESF calibration
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beads and QuickCal program v. 2.3 (Bangs Laboratories, Inc., Fishers, IN) according to the
instructions of the manufacturer.
2.8. Fluorescent ligand binding experiments with cells using FCM or with membranes in
suspension
Fluorescent ligand binding experiments with cells using FCM were performed as follows.
CHO or HEK293 cells expressing ARs were incubated with different concentrations of
MRS5218 ranging from 5 nM to 1,000 nM for various times, as indicated, at 37 °C in 6-, 12-
or 24-well plates. Nonspecific binding was determined in the presence of the selective
nonfluorescent antagonist MRS1220 (10 µM) for studies with the hA3AR or with NECA
(100 µM) in studies with the mA3AR. To determine the fraction of membrane-bound
fluorescent agonist, we blocked the internalization of MRS5218 in some experiments with
either a 15 min preincubation with 0.4 M sucrose containing media or an incubation at 4 °C
[12,14,27].
Transfected CHO and HEK293 cells were prepared for FCM as described previously [16].
Briefly, cells were washed 3 times with ice-cold PBS, detached with 0.2 % EDTA, which
was neutralized with media after 5 min incubation at 37 °C. Cell suspensions were
transferred to polystyrene round-bottom BD Falcon tubes (BD, Franklin Lakes, NJ), and
centrifuged twice at 400 × g for 5 min. Cells were then suspended in PBS and proceeded to
FCM using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ), with a 635 nm laser.
Mean fluorescent intensities (MFIs) were recorded in FL-4 channel in log mode. In
competitive binding assays, cells were analyzed using an AMS system autosampler (Cytek,
Fremont, CA) for a FACSCalibur. For FCM assays with undifferentiated HL-60 cells that
grow in suspension, cells (1 × 106 in 0.5 ml) were transferred to polystyrene tubes in culture
media containing 20 mM HEPES (pH 7.4) and incubated with MRS5218 (300 nM) for 1 h,
after which the cells were pelleted (400 × g for 5 min) and washed once with ice-cold PBS.
The cells were resuspended in culture media with HEPES and subjected to analysis by FCM.
For FCM competitive binding experiments in hA3AR-CHO cells using MRS5218 as
fluorescent tracer, cells were grown in 96-well plates. The cells were split to reach a final
concentration of 2 × 105 cells/ml in a round- or flat-bottom 96-well plate and used when
confluency reached 70% (16 h). The medium was aspirated, and sucrose medium (0.2 ml of
0.4 M) was added to each well. After 15 min, MRS5218 (30 nM) and the test compound (at
5 different concentrations) were added in the wells. After 1 h incubation at 37 °C, the
medium was aspirated, and cells were washed 3× with 0.2 ml PBS without calcium. Then
cells were treated with 0.2 ml of 0.2 % EDTA solution in PBS without calcium and
incubated at 37 °C for 15 min. The plate was then placed in a shaker for 15 min at 24 °C at
700 rpm.
2.7. Data analysis
All data were analyzed by non-linear least squares analysis and Ki values were calculated
using Prism (GraphPad Software, San Diego, CA) for all assays. IC50 values were converted
to Ki values as described [28].
3. Results
3.1. Prioritization of fluorescent probes based on radioligand binding affinity
The fluorescent derivatives were compared in radioligand binding affinity and selectivity at
the hA3AR in membranes of receptor-expressing CHO cells (Table 1). It has already been
shown that varying the fluorophore and the linker on the same pharmacophore affects the
affinity of a fluorescent probe toward ARs [29,30]. Here we have compared the feasibility of
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fluorescent receptor labeling using conjugates in which the A3AR pharmacophore and
fluorophore were linked through click chemistry to form a triazole ring (i.e. 4, 5, 7 and 8),
by amide formation (1 and 6) or by a Sonogashira carbon−carbon bond forming reaction (2
and 3) [19,21,22]. The previously reported derivatives 1, MRS5218, and 2, MRS5704,
displayed the highest affinity with Ki values of 17.2 and 68.3 nM, respectively [21,22].
These derivatives at 10 µM were also characterized as nearly full agonists of the A3AR in
inhibition of adenylate cyclase in AR-transfected CHO cells, with 94.4% and 77.8% of
maximal efficacy of NECA, respectively [21,22]. The remaining nucleoside derivatives (3 –
8) containing various fluorophores tethered from the adenine C2 or N6 position were less
potent in hA3AR binding. Furthermore, MRS5218 was shown to be a full agonist at the
A3AR [22]. Therefore, MRS5218 and MRS5704 were the most promising derivatives for
comparison in subsequent experiments using whole cells.
Both MRS5218 and MRS5704 [19,20] contained a fluorophore linked through the C2
position of the adenine ring. Furthermore, N6-(3-chlorobenzyl) and rigid (N)-methanocarba
ring modifications that enhanced A3AR selectivity were present. In one case (MRS5218),
the fluorophore, Cy5 (a cyanine dye that absorbs in the orange region and fluoresces in the
red region), was tethered at a distance from the C2 position by a flexible amide chain. In the
other case (MRS5704), the fluorophore consisted of a rigid polycyclic 1-pyrenyl moiety that
was coupled to the pharmacophore through an ethynyl group extending from the C2
position.
The lipid-dependent interactions of pyrene fluorophores with artificial membranes have
been studied [31]. As expected, the absorption and emission spectra of the pyrene derivative
MRS5704 were solvent-dependent (Figure 2). The extended conjugated system of MRS5704
was found to provide a longer wavelength of emission in methanol (~430 nm) than pyrene
itself (~390 nm). To test receptor binding, we measured the changes in fluorescence with
different concentrations of MRS5704 upon adding 50 µg/well hA3AR-expressing CHO cell
membranes and incubating for 5 or 60 min (data not shown). Excitation was at 384 nm, and
the fluorescence was measured at 430 and 508 nm. The fluorescence at 508 nm varied solely
with the concentration of MRS5704 and was independent of the amount of membrane
added. However, the fluorescence at 430 nm was dependent not only on the concentration,
but on the incubation time as well. Increasing the concentration of cell membranes in the
suspension significantly increased the fluorescence of MRS5704, which could not be
blocked at any wavelength in the presence of hA3AR antagonist MRS1220 (10 µM).
Therefore, the changes in fluorescence were not dependent on a specific interaction with the
hA3AR in membranes.
MRS5704 was examined using FCM in AR-expressing HEK293 cells, and under these
conditions it also failed to show specific fluorescent binding to the mA3AR or hA3AR. The
traces from A3AR-expressing cells and from control cells were nearly identical. Therefore,
the Cy5 derivative MRS5218 was used in subsequent fluorescent experiments with the
A3AR due to its specific binding, relatively high affinity and fluorescence emission
spectrum that does not overlap autofluorescence of the cells.
3.2. Fluorescence microscopy experiments
The absorption and emission spectra of MRS5218 were determined in methanol (data not
shown) indicating peak absorption at 650 nm and peak emission at 674 nm. With these
fluorescence parameters typical of Cy5, the time course of binding to whole cells was
probed microscopically. Fluorescence micrographs showing the binding of 70 nM MRS5218
to the hA3AR expressed in CHO cells at different time points are shown in Figure 3. After a
5 min incubation period, the fluorescence was highly associated with the plasma membrane,
but with longer time periods it progressively became more associated with the intracellular
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compartment and less with the cell membrane. After 2 h incubation with hA3AR-expressing
CHO cells, the fluorescence was mainly intracellular. This was consistent with the rapid
characteristic desensitization and internalization of the hA3AR upon agonist binding, as
reviewed by Klaasse et al. [8]. In the corresponding control experiments performed in the
absence of MRS5218, cell fluorescence was not observed, due to the lack of
autofluorescence of cells at the excitation wavelength of the Cy5 dye (674 nm).
3.3. Fluorescent ligand binding experiments with FCM
We varied the concentration of fluorescent ligand MRS5218 from 5 nM to 200 nM and used
FCM to determine the measured fluorescence intensity (MFI) of the ligand present on or
within the cell, i.e. either receptor-bound at the surface or internalized. Saturation curves for
binding of MRS5218 to CHO cells expressing the hA3AR were obtained using Molecules of
Equivalent Soluble Fluorochrome (MESF) values (Figure 4) [26]. CHO cells expressing the
hA3AR were used to measure autofluorescence in the absence of fluorescence ligand, and
nonspecific binding was measured in the presence of both MRS5218 and 10 µM MRS1220.
The specific binding of fluorescent signal to the cells appeared to be saturable, and the ratio
of specific to nonspecific binding was very high. From the saturation curve, an apparent
binding constant (Kd app) was determined to be 16.1±4.3 nM. This parameter is not directly
comparable to a Kd determined for equilibrium binding to a cell surface receptor, because it
is likely to represent a composite of surface binding of the label and receptor internalization
processes.
The binding saturation procedure was modified to separate surface-bound label from
internalized fluorescence. Incubation for one hour at 4 °C or treatment with sucrose, both of
which are known to inhibit the internalization of cell surface GPCRs [12], significantly
lowered the maximal fluorescent intensity (Bmax=58,655 and 192,689 MESF, respectively,
compared to Bmax=245,974 MESF using 37 °C incubation in sucrose-free media), with
Kd app values of 46.9±23.5 nM and 31.4±4.6 nM , respectively (Figure 4). At low
temperature, the rate of ligandreceptor binding will be slower (similar to other AR agonists
[32]), which may explain why the slope of the curve at 4 °C was less steep than that of the
sucrose curve.
The kinetics of MRS5218 binding in CHO cells expressing the hA3AR was studied using
FCM. The rate of association of the fluorescently labeled MRS5218 (30 nM) was measured
in the absence or presence of 0.4 M sucrose. We found that the association of the fluorescent
compound occurred rapidly (within 30 min), and by the end of the incubation period about
half of the observed fluorescence was internalized (Figure 5A). The association of
MRS5218 was slower when receptor internalization was blocked (t1/2=17.6 min in sucrose-
free media and 26.4 min in sucrose-containing media).
The rate of dissociation of the fluorescent label from CHO cells expressing the hA3AR was
measured by FCM (Figure 5B). Dissociation of MRS5218 (30 nM), in the presence of 0.4 M
sucrose to prevent internalization, was initiated after 60 min of incubation at 37 °C by
adding 10 µM MRS1220. A t1/2 value of 21.4 min for dissociation of surface-bound
fluorescence was observed. The rate and degree of internalization of fluorescent agonist
were determined as follows. Cells were incubated with 30 nM MRS5218 for different time
intervals at 37 °C, and cell-surface bound ligands were removed using three 5 min washes
with medium at pH 3.5. The remaining cell fluorescence represented internalized MRS5218,
which was measured by FCM. The t1/2 of internalization was 12.9 min, and it reached a
plateau after 45 min (Figure 5C), at which point roughly 50% of the fluorescent label was
internalized, i.e. similar to the fraction of internalization as determined with inhibition by
sucrose.
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Competition for fluorescent binding with known AR ligands was performed using FCM in
the presence of sucrose. To determine the Ki values of known ligands, we used MRS5218 as
a tracer, at a concentration of 30 nM (close to its Kd value). Competitive binding results with
known agonists and chemically diverse antagonists are shown in Table 2. The observed
pharmacology of agonists in this whole cell FCM assay (Figure 6) corresponded to that
previously observed for the hA3AR. However, the correspondence of the affinity of known
antagonists with that determined by FCM was mixed, i.e. the determined affinity of
MRS1220 was roughly 10-fold lower than its known hA3AR binding affinity and the
affinity of XAC was closer to the previously reported value.
3.4. Radioligand binding and fluorescent binding with FCM at mARs
In the radioligand binding assays in membranes of mAR-expressing HEK cells (Table 1),
MRS5218 was found to bind with moderate affinity at the mA3AR (Ki 261 nM) but not
selectively in comparison to mA1AR (Ki 143 nM) and mA2AAR (Ki 717 nM). However, in
FCM assays with whole cells, MRS5218 at concentrations as high as 300 nM specifically
labeled mA3AR-HEK293 cells versus cells expressing other AR subtypes (Figure 7). At a
concentration of 1 µM, specific binding of MRS5218 to mA2BAR-HEK293 cells became
detectable (Figure 7), but this was not observed for mA1 or mA2AAR subtypes. In
saturations assays with whole cells, MRS5218 was found to bind to the mA3AR in the
absence of sucrose with a Kd app of 7.52±0.49 nM, which is substantially lower than that
determined in radioligand binding assays with membranes (Table 1), and with a Bmax of
99,420±18,110 MESF/cell (Figure 8A). In kinetic FCM binding assays, MRS5218 (5 nM)
associated rapidly (t1/2 = 37.8±2.9 min) with the mA3AR (Figure 8B). After incubation at a
concentration of 5 nM for 2 h to achieve equilibrium, the t1/2 for MRS5218 to dissociate
from mA3AR-expresssing HEK293 cells was observed to be 39.4±4.2 min (Figure 8C). The
binding affinity (Kd) of MRS5218 determined from the kinetic binding data was calculated
to be ~126 nM according to the following equation: [Kd = Koff / (obs Kon – Koff/ ligand
concentration)].
3.5. FCM binding experiments with HL-60 cells
We examined if the specific binding of MRS5218 to the A3AR could be seen in a native cell
line expressing the receptor. Human promyelocytic leukemic HL-60 cells, which have been
reported to express the A3AR [33], were incubated with 300 nM MRS5218 for 1 h in the
presence of 100 nM XAC to prevent binding to A1, A2A and A2BARs; the cells were washed
and then subjected to analysis by FCM. As shown in Figure 9, specific binding of MRS5218
to HL-60 cells was detected in these assays, which appears to be attributable to binding to
the A3AR based on displacement by 1 µM of the potent, selective A3AR antagonist
MRS1523 [34]. The extent of displacement by MRS1523 was similar to that produced by 1
µM NECA.
4. Discussion
Three new fluorescent nucleosides were synthesized in the series of (N)-methanocarba
adenosine derivatives, which has members with excellent selectivity and sub-nanomolar
potency toward the hA3AR [19,21,22]. In order to be able to visualize the A3AR, various
fluorophores with different linker lengths were attached through the N6 position or through
an ethynyl group extending from the C2 position. The 5′-N-methyluronamide group was
included in all for the purpose of maximizing A3AR agonist efficacy, and the (N)-
methanocarba modification of the ribose ring tended to increase selectivity. A total of eight
fluorescent nucleosides were compared; based on human A3AR binding affinity and bound
fluorescence, we narrowed the group to the most promising derivatives, MRS5218 and
MRS5704, and studied their interaction with cells expressing the human or mouse A3AR. In
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both cases, the adenosine pharmacophore contained a 3-Cl-substituted N6-benzyl group that
favored affinity/selectivity at the A3AR.
During spectral characterization, we could not observe the well-known vibrational structure
in the absorption spectra of MRS5704, which corresponds to the previously described
behavior of pyrene derivatives; it has already been reported that the vibrational structure of
the pyrene absorption spectra is lost upon more complex derivatization. Here, MRS5704
contains attached adenine and ethynyl moieties that may be able to interact with the π-
system of pyrene, especially in polar solvents [35].
The fluorescence spectra of pyrene-containing molecules typically increases upon increasing
solvent polarity [36]. However, we observed a significant decrease in the fluorescence and
also in the absorption of the pyrene derivative MRS5704. This altered behavior may derive
from the different molecular structure, the different excitation wavelength used or from
aggregaton of the hydrophobic solute created upon serial dilution with PBS [37].
We proposed that upon transfer from a polar to a nonpolar environment (i.e. upon receptor
binding) we would observe changes in fluorescence intensity. We recorded increases in
fluorescence upon membrane addition; however, the cell-bound fluorescence of MRS5704
proved to be unrelated to receptor binding. It has been reported that due to its apolarity, the
pyrene moiety tends to bind preferentially nonspecifically within the phospholipid bilayer
[38]. Our ligand has increased fluorescence in non-polar solvents, unlike previous
observations with pyrene and its less complex derivatives, and a similar increase in
fluorescence upon membrane binding was consistent with nonspecific membrane
localization.
Therefore, MRS5704 was found to be too hydrophobic to be used as a ligand binding probe
for the A3AR. Thus, in designing new fluorescent ligands for GPCRs, it is necessary to take
into account other physicochemical properties, in addition to the receptor binding affinity.
However, MRS5218 was a useful fluorescent probe for characterizing the A3AR. At 30 nM,
roughly half of the bound fluorescence after 90 min incubation period was internalized, as
determined using acid wash and sucrose, in qualitative agreement with the microscopic
images (Figure 3). Unlike antagonist ligands of the A3AR and other GPCRs that bind
predominantly at the cell surface [16], the agonist probes are internalized by well-
characterized processes [8].
Trincavelli et al. investigated agonist-induced endocytosis and recycling of the hA3AR using
[125I]AB-MECA with CHO cells expressing the A3AR, and they found that the
internalization occurs with a t1/2 of 17 min [11, 12]. However, removal of the agonist led to
recycling of the receptors with a t1/2 of 35 min, while the cAMP signal was resensitized
within 120 min. A fluorescently-labeled agonist of the Gs-coupled A2AAR stimulated
adenylyl cyclase and was a useful tool for tracking receptor internalization [14]. Using
hyperosmolaric sucrose to inhibit clathrin-mediated endocytosis, internalization of this label
and its localization to early endosomes were shown to be receptor-dependent via clathrin-
coated vesicles. Similarly, in the present study, sucrose inhibited internalization of a
fluorescent agonist of the Gi-coupled A3AR.
For use with whole cells, as in FCM, the agonist fluorescent probes provide an advantage
over antagonists in the determination of the relative level of expression of the receptor,
because the internalization concentrates such probes intracellularly. Thus, binding of a
fluorescent agonist can provide an amplification process to increase the signal, which could
be particularly valuable when the receptor surface expression level is low. In addition, it
indicates the initial presence of receptors capable of activation on the cell surface. In the
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present studies, we provide evidence that MRS5218 may be useful in detecting surface
expression of the A3AR in the human HL-60 promyelocytic cell line by FCM, although
further validation experiments using “knock-down” approaches are required. Chen and
colleagues [33] previously demonstrated that HL-60 cells prominently express the A3AR,
which is involved in amplifying signaling cascades involved in chemotaxis, and its
expression increased upon differentiation. Several A3AR-selective ligands currently in
clinical development are agonists [2]. Therefore, by this method one can detect and perhaps
quantify the presence on the cell surface of receptors that are amenable to modulation by
agonist ligands.
The nonspecific binding associated with MRS5218, determined by co-administration of
either a potent, nonfluorescent A3AR antagonist (MRS1220) or a potent agonist (NECA),
was too low to quantify (Figure 4). This indicated that the majority of the fluorescent label
bound to the cell and entered through receptor-mediated processes, rather than by
nonspecific membrane association or diffusion.
We found that the Ki value for MRS5218 determined using CHO cell membranes expressing
the hA3AR and [125I]I-AB-MECA (17.2 nM) was comparable to the apparent binding
constant (Kd app 31.4 nM) determined by saturation using the FCM assay with intact cells in
the absence of sucrose. In contrast, a much higher affinity of MRS5218 was calculated with
intact HEK293 cells expressing the mA3AR compared to assays with membrane
preparations (~35-fold higher Kd value). It has been reported that GPCRs can assume
multiple agonist-selective active conformations due to protein-protein interactions, which
can lead to changes in binding affinity and intracellular signaling mechanisms (biased
agonism) [39]. These interactions can vary between cell types for the same receptor.
Therefore, we speculate that the differences in binding affinity observed in assays with
intact cells and isolated membranes may be related to loss of the influence of allosteric
interactions with intracellular proteins. The binding affinity in cell-based assays of a given
ligand can also be influenced by dynamic processes, such as regulation of G protein
coupling and cellular trafficking of the receptors [8]. The influence of these processes,
which likely vary between cell types, might also account for the differences observed
between the experiments. These processes might also underlie the different Kd values
calculated for MRS5218 binding to the murine A3AR in FCM assays when using results
from kinetic binding assays versus equilibrium saturation binding assays. Considering that
roughly half of the fluorescence detected in the FCM assays reflected binding to receptors
that had been internalized, it was somewhat surprising that the dissociation rate of MRS5218
was found to be so rapid. This observation further supports the idea that the A3AR recycles
rapidly following agonist exposure. The dynamic nature of the A3AR compared to the other
AR subtypes might explain the observation that MRS5218 exhibited binding selectivity for
the A3AR in the cell-based binding assays with murine receptors.
A further advantage of a fluorescent agonist probe for the A3AR is in the screening of
agonist ligands. The use of antagonist fluorescent probe MRS5449 was previously shown to
be suitable for screening of antagonists, but not agonists in whole cells using FCM [16].
Here, we observed the converse, i.e. FCM competition for fluorescent binding with known
AR agonists, but antagonist affinities did not consistently reflect expected affinities. This
might relate to the fact that the radioligand binding Ki values were determined in cell
membranes and the FCM assay in whole cells.
In conclusion, we now have identified a preferred fluorescent agonist ligand MRS5218 that
is selective for the A3AR and displays relatively high affinity and low nonspecific binding in
various models. The far red-fluorescing cyanine5 dye avoids interference from the
autofluorescence of cells. The feasibility of using this click-linked conjugate has been
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demonstrated at both human and mouse A3ARs, and the affinities of known AR agonists at
the hA3AR were correctly determined. The amount of fluorescence specifically bound to
receptors on the surface of hA3AR-expressing cells can be separated from internalized label
by various methods to demonstrate that at least half of the cell-associated label internalized
rapidly corresponding to the known properties of the A3AR. This probe now can be added to
the armamentarium of fluorescent ligands that may be utilized in drug discovery for various
AR subtypes.
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Abbreviations
cAMP 3′,5′-cyclic adenosine monophosphate
CHO Chinese hamster ovary
Cl-IB-MECA 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-
N-methyl-β-D-ribofuranuronamide
DMEM Dulbecco's Modified Eagle Medium
DMSO dimethyl sulfoxide
FBS fetal bovine serum
PBS phosphate buffered saline
FCM flow cytometry
GPCR G protein-coupled receptor
HEK human embryonic kidney
[125I]I-AB-
MECA
[125I]4-amino-3-iodobenzyl-5′-N-methylcarboxamidoadenosine
IB-MECA 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-
methyl-β-D-ribofuranuronamide
MESF molecules of equivalent soluble fluorochrome
MFI measured fluorescent intensity
MRS1220 N-[9-chloro-2-(2-furanyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-
yl]benzene acetamide
MRS5218 (1′S,2′R,3′S,4′S,5′S)-4′-[6-(3-chlorobenzylamino)-2-(N-cyanine(β-
aminoethylaminocarbonyl)-1-butynyl)-9-yl]-2′,3′-
dihydroxybicyclo[3.1.0]hexane-1′-carboxylic acid N-methylamide
MRS5449 2-(6-amino-3-iminio-4,5-disulfonato-3H-xanthen-9-yl)-5-((6-(4-(4-((9-
chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)amino)-4-
oxobutyl)-1H-1,2,3-triazol-1-yl)hexyl)carbamoyl)benzoate
MRS5704 (1S,2R,3S,4R,5S)-4-(6-(3-chlorobenzylamino)-2-(pyren-1-
ylethynyl)-9H-purin-9-yl)-2,3-dihydroxy-N-
methylbicyclo[3.1.0]hexane-1-carboxamide
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NECA 5′-N-ethylcarboxamidoadenosine
XAC xanthine amine congener, N-(2-aminoethyl)-2-[4-(2,3,6,7-
tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide
hydrochloride
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Figure 1.
Structures of the fluorescent A3AR agonist ligand probes used in this study.
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Figure 2.
A. Absorbance spectra of 10 µM MRS5704 in solvents of different polarity (DMSO,
methanol, Tris buffer, PBS). All spectra were recorded using a SpectraMax M5 microplate
reader with a cuvette (solution) or 96-well black plates (membranes). MRS5704 in DMSO
solution has three maxima in the absorbance spectra at 282, 372 and 398 nm. However, in
more polar buffers like methanol or PBS, the absorption is lower and slightly red-shifted
with maxima at 285, 384 and 410 nm. B. Fluorescence spectra of 10 µM MRS5704 in
DMSO and PBS using 384 nm excitation wavelength. MRS5704 shows maximum at 508
nm in PBS and at 437 and 455 nm in DMSO. It is noteworthy that the fluorescence in a
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more polar solvent (PBS) not only shifted to longer wavelength, but the amplitude was
significantly decreased.
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Figure 3.
Fluorescence micrograph of 70 nM MRS5218 bound to hA3AR expressed by CHO cells
following incubation for the indicated times: A) 5 min; B) 15 min; C) 30 min; D) 60 min; E)
90 min; F) 120 min. hA3AR-expressing CHO cells in the absence of any fluorescence ligand
were used as controls, but cell fluorescence was not observed. The images were acquired
with Zeiss Axioimager D1 equipped with a filter set 50 (Zeiss) with excitation and emission
wavelengths at BP640/30 nm and BP690/50 nm, respectively.
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Figure 4.
Saturation binding assays with MRS5218 using FCM following incubation for 1 h with the
hA3AR expressed in CHO cells in the absence or presence of different inhibitors of receptor
internalization. Fluorescent intensity values of small molecule-cell conjugates were
measured using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ) with a 635 nm
laser, FL4 channel and log mode and Cell Quest Pro software (BD, Franklin Lakes, NJ).
MFIs were converted to MESF (Figures S5 and S6) values using QuickCal program v. 2.3
(Bangs Laboratories, Inc., Fishers, IN). Nonspecific binding was measured in the presence
of 10 µM MRS1220. The apparent Kd values were determined to be 16.1±4.3 nM (without
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blocking internalization), 31.4±4.6 nM (0.4 M sucrose in the media) and 46.9±23.5 nM (4
°C incubation). Results are expressed as mean ± S.E. (n=3).
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Figure 5.
Kinetics of MRS5218 binding to the hA3AR expressed in CHO cells determined using
FCM. Each graph represents the average of three experiments. A) Association in the absence
or presence of 0.4 M sucrose at 37°C and in absence of sucrose at 4°C. Cells were incubated
with 30 nM MRS5218 for different time intervals from 5 min to 180 min. The observed
association rate constant (K) was 0.039 min−1 for the incubation in absence of sucrose at
37°C, K = 0.026 min−1 for the incubation in presence of sucrose at 37°C and K = 0.013
min−1 for the incubation at 4°C, determined by fitting a one phase exponential association
equation to the obtained data. B) Association followed by dissociation of MRS5218 (30 nM)
initiated at 60 min by the addition of 10 µM MRS1220, measured in the presence of 0.4 M
sucrose at 37°C. The observed t1/2 of the dissociation was 21.4 min. C) Internalization
kinetics of 30 nM MRS5218. Cells were incubated with 30 nM MRS5218 for different time
intervals from 5 min to 90 min. Internalized amount (%int) was calculated as the acid
insensitive fluorescence at x time point (MESFx) compared to total MESF (MESFtotal) and
corrected with the nonspecific binding (MESFnonspec): %int = (MESFx - MESFnonspec) /
(MESFtotal - MESFnonspec). The acid-insensitive binding of MRS5218 was measured after
removing cell-surface bound ligand by 3 × 5 min acid wash (pH 3.5). After 90 min of
incubation, the percentage of internalized MRS5218 was 47.6%. The t1/2 of the
internalization was 12.9 min.
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Figure 6.
Inhibition of fluorescent binding by known AR ligands (Cl-IB-MECA, CPA and XAC)
using FCM. Competitive binding assay was performed using CHO cells expressing the
hA3AR incubated with 30 nM MRS5218 and increasing concentrations of the adenosine
receptor ligands for 60 min at 37 °C in the presence of 0.4 M sucrose. The Ki values are
(nM) 1.3±0.3, 88.4±13.5 and 17.6±3.6; respectively. Results are expressed as mean±S.E. (n
= 3).
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Figure 7.
Flow assays using HEK293 cells expressing mARs. The cells were incubated with 50, 300
or 1,000 nM MRS5218 for 2 h before being prepared for analysis by FCM. Non-specific
binding was determined in these assays by including 100 µM NECA in the incubations.
Histograms plotting cell counts versus mean fluorescence intensity per cell is shown.
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Figure 8.
A) Saturation binding in FCM assays using HEK293 cells expressing the mA3AR. The data
are plotted as MESF values versus the concentration of MRS5218. B) Association and C)
dissociation kinetics of MRS5218 binding to the mA3AR expressed in HEK293 cells by
FCM. For the saturation assays, the cells were incubated with increasing concentrations of
MRS5218 for 2 h prior to measurement of fluorescence. In the kinetic binding assays,
MRS5218 was used at a concentration of 5 nM. Cells were incubated with MRS5218 for 2 h
in the dissociation studies after which fluorescence was measured at the times indicated
following the addition of NECA (100 µM). Results of a representative experiment
performed in triplicate are shown. Average binding parameters (mean±SEM) from three
experiments are summarized in the figures.
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Figure 9.
Flow assays using HL-60 cells. Cells were incubated with 300 nM MRS5218 for 1 h in the
presence of 100 nM XAC before being prepared for analysis by FCM. Binding was
determined after the addition of 100 µM NECA or 1 µM MRS1523. A) Histogram data from
a representative experiment plotting cell counts versus fluorescence intensity. B) Averaged
data (mean±SEM) from 6 independent experiments. * P<0.05 versus total binding by one-
way ANOVA followed by post-hoc analysis using a t-test and the Bonferoni correction.
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Table 2
Inhibition of A3AR binding of known AR agonists and antagonists using MRS5218 (30 nM) as a FCM tracer
in whole cells.a
Compound hA3AR radioligand
binding, Ki (nM)b
FCM binding at
hA3AR, Ki(nM)
Agonists
Cl-IB-MECA 1.4 1.3±0.3
IB-MECA 1.8 2.7±0.4
NECA 25 73.6±7.9
CPA 72 88.4±13.6
Antagonists
MRS1220 0.65 5.9±0.7
XAC 13.8 17.6±3.6
a
Incubation of A3AR-expressing CHO cells with MRS5218 (30 nM) for 60 min at 37 °C was performed in the presence of 0.4 M sucrose (60 min).
The inhibitors were added 15 min prior to the fluorescent tracer. Ki values represent the mean of at least three replicates.
b
Ki values for A3AR binding affinity in cell membrane preparations using [125I]I-AB-MECA are reported [16 and references therein].
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